ESR1 and breast carcinoma: The immunohistochemical detection of cancer biomarkers that guide treatment has been well validated, and some of them, such as ER and progesterone receptor (PgR) in breast cancer, have been approved by the Food and Drug Administration (FDA) (O’Hurley et al. 2014).